Please wait a minute...
European Journal of Gynaecological Oncology  2018, Vol. 39 Issue (2): 310-313    DOI: 10.12892/ejgo3859.2018
Case Report Previous articles | Next articles
Recurrent endometriosis following tibolone hormone replacement therapy after mucinous ovarian carcinoma
B.D. de-la-Noval1, *(), M.D. Diestro Tejeda1, L. Yébenes2, I. Zapardiel1, A. Hernández Gutiérrez1, J. De-Santiago García1
1 Gynaecology Oncology Unit, Gynaecology and Obstetrics Department, Hospital Universitario La Paz, Madrid, Spain
2 Pathological Anatomy Department; Hospital Universitario La Paz, Madrid, Spain
Download:  PDF
Export:  BibTeX | EndNote (RIS)      
Abstract  
The aim is to describe an atypical clinical case of endometriosis in a young patient with surgically induced menopause due to an ovarian mucinous carcinoma. Case Report: A 34-year old woman with deep endometriosis developed a large mass occupying the whole abdominal cavity, without ascites or carcinomatosis. A decisional laparoscopy and complete surgical staging were performed according to a FIGO Stage IA ovarian mucinous carcinoma. The patient required hormonal replacement therapy with tibolone. A year later, an endometriotic nodule appeared in the bladder, and two years after, endometriosis on the bowel and the vaginal vault without evidence of tumoral relapse also occurred. The patient was referred to the obesity unit and discontinued tibolone, with clinical and radiological stabilization. Conclusion. Tibolone should be used with caution in patients with a previous history of endometriosis and it is recommended to avoid hyperestrogenic situations in gynaecological malignancies in hormone-dependent diseases.
Key words:  Endometriosis      Epithelial ovarian cancer      Mucinous adenocarcinoma      Obesity      Tibolone     
Published:  10 April 2018     
*Corresponding Author(s):  B. DíAZ-DE-LA-NOVAL     E-mail:  begodelanoval@gmail.com

Cite this article: 

B.D. de-la-Noval, M.D. Diestro Tejeda, L. Yébenes, I. Zapardiel, A. Hernández Gutiérrez, J. De-Santiago García. Recurrent endometriosis following tibolone hormone replacement therapy after mucinous ovarian carcinoma. European Journal of Gynaecological Oncology, 2018, 39(2): 310-313.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo3859.2018     OR     https://ejgo.imrpress.com/EN/Y2018/V39/I2/310

[1] Gen-Hai Zhu, Kang Wang, Lan Hong, Xin-Hui Fu, Fu-Jin Liu, Hai-Yan Huang. Safety and efficacy of fertility-sparing surgery for an orthotopic xenograft model of epithelial ovarian cancer in nude mice[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 609-616.
[2] Marcin Jedryka, Agnieszka Chrobak, Anna Chelmonska-Soyta, Daria Fijalkowska, Rafal Matkowski. Decreased expression of estrogen receptors alpha and beta in peripheral blood lymphocytes from the endometrial cancer patients and women with endometriosis[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 375-379.
[3] Emine Karabuk, Burak Karadag, Ceyda Karadag, M. Faruk Kose, M. Murat Naki, E. Nilufer Guler. The outcomes of fertility sparing surgery in epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 391-395.
[4] Chenchen Zhu, Hanyuan Liu, Zhen Shen, Yanhu Xie, Tianjiao Zhang, Björn Nashan, Dabao Wu, Ying Zhou. Treatment and survival outcomes from epithelial ovarian cancer in women aged 65 years or older[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 415-421.
[5] Can Fang, Yan Zhao, Kezhen Li, Danhui Weng, Peng Wu, Gang Chen, Ding Ma, Juncheng Wei. Diabetes mellitus and epithelial ovarian cancer in Chinese women: a retrospective cohort study[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 260-264.
[6] X.Z. Cheng, Z. Zhou, M.Y. Yang, Y.L. Cai, F. Deng, X.X. Chen. Prognostic factors for types I and II epithelial ovarian cancer in the elderly[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 7-15.
[7] S. Kim, K. J. Min, S. Lee, J. H. Hong, J. K. Lee, N. W. Lee, J. Y. Song. Clear cell carcinoma arising from abdominal wall endometriosis with lymph node metastasis – a rare case report and review of the literature[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1047-1050.
[8] A. Temtanakitpaisan, K.-G. Huang, T. Temtanakitpaisan. Metachronous contralateral ovarian cancer after interval successful pregnancy[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1091-1092.
[9] J.-Y. Zhou, Y. Zou, L.-Q. Wang, S.-F. Fang, Y. Luo, Q.-H. Xie, F. Wang, O.-P. Huang. Novel CARD14 mutations in Chinese samples with ovarian endometriosis[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 765-769.
[10] Yoshiya Miyahara, Hitomi Imafuku, Yuka Murata, Yasuhiko Ebina, Hideto Yamada. A retrospective analysis of giant ovarian tumors weighing more than 5,000 grams[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 563-566.
[11] S. Kabukcuoglu, B. Hayit. Histopathologic features of advanced stage endometrial carcinoma[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 614-618.
[12] V. Pažin, A. Dobrosavljevic, L. Nejkovic. Primary fallopian tube carcinoma – case report[J]. European Journal of Gynaecological Oncology, 2019, 40(1): 163-165.
[13] M. Terzic, S. Terzic, J. Dotlic, M. Dokic, M. Mitrovic, G. Bapayeva, N. Arsenovic, A.S. Lagana, M. Norton. Ovarian clear cell carcinoma associated with endometriosis: a case report and literature review[J]. European Journal of Gynaecological Oncology, 2019, 40(1): 166-169.
[14] Chen Mi, Cancan Zhang, Qi Zhang, Aiyun Xing. Increased expression of lncRNA HULC in human epithelial ovarian cancer and its biological functions[J]. European Journal of Gynaecological Oncology, 2018, 39(6): 992-996.
[15] Jing Zhao, Xue Dong, Qing-cui Liu, Qun Lu. Expression of plasma miR-106a in epithelial ovarian cancer and its diagnostic and prognostic significance[J]. European Journal of Gynaecological Oncology, 2018, 39(5): 769-772.
No Suggested Reading articles found!